Corporate Profile

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

 

lnk Overview

Read More

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

lnk Stock Information

View All Stock Information

lnk Stock Information

View All Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

lnk Stock Information

View All Stock Information

News Releases

News and views about the Intercure.

13-Oct-21

InterCure to Present in Benzinga Cannabis Capital Conference

NEW YORK and TORONTO and HERZLIYA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will present at the Benzinga Cannabis Capital Conference
12-Oct-21

InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501
03-Sep-21

InterCure Re-Announces its Record-Breaking Second Quarter Financial Results With 4 Times YOY Revenue Growth - Following NASDAQ Listing

Achieved record revenue of NIS 45 million (over CAD$17 million), an increase of 400% year-over-year and 37% quarter-over-quarter Achieved quarterly run-rate Q2 Pro Forma 1 revenues of NIS 55 million (over CAD$21 million) Recorded continued increase in operating profit, EBITDA 2 and net profit

lnk News

Events
Investor events will be posted soon.

lnk Events

View All Events
Featured Reports
Aug 17, 2021
Aug 17, 2021
Aug 17, 2021
Aug 17, 2021